Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.60 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | P4HB | P07237 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 9/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | POLB | P06746 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | RECQL | P46063 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908244 | 1.00 | HSD17B3 (0.60) | HSD17B3NLRP3P4HBMEN1KMT2A | |
| SCHEMBL13855093 | 0.88 | HSD17B3 (0.58) | HSD17B3NLRP3P4HBMEN1KMT2A | |
| SCHEMBL3905762 | 0.85 | MAP3K5 (0.67) | HSD17B3NLRP3P4HBMEN1KMT2A | |
| SCHEMBL3905766 | 0.85 | MAP3K5 (0.67) | HSD17B3NLRP3P4HBMEN1KMT2A | |
| SCHEMBL3907485 | 0.84 | MEN1 (0.67) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL3907489 | 0.84 | MEN1 (0.67) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL3904812 | 0.81 | MEN1 (0.77) | HSD17B3NLRP3P4HBMEN1KMT2A | |
| SCHEMBL3904810 | 0.81 | MEN1 (0.77) | HSD17B3NLRP3P4HBMEN1KMT2A | |
| SCHEMBL6791455 | 0.79 | PTPN12 (0.73) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL8289212 | 0.79 | MAP3K5 (0.61) | HSD17B3NLRP3P4HBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | HSD17B3 3437/4885NLRP3 3708/4885P4HB 4086/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | HSD17B3 3742/4885NLRP3 3171/4885P4HB 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.